Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

The Lancet

Volumn 390, Issue 10104, 2017, Pages 1747-1757

  Sibbing, Dirk ^a,b,s   Aradi, Dániel ^c   Jacobshagen, Claudius ^d,s   Gross, Lisa ^a,s   Trenk, Dietmar ^e,s   Geisler, Tobias ^f,s   Orban, Martin ^a,s   Hadamitzky, Martin ^g   Merkely, Béla ^c,s   Kiss, Róbert Gábor ^h,s   Komócsi, András ^i,s   Dézsi, Csaba A ^j   Holdt, Lesca ^k,s   Felix, Stephan B ^l   Parma, Radoslaw ^m,s   Klopotowski, Mariusz ^n,s   Schwinger, Robert H G ^o   Rieber, Johannes ^p,s   Huber, Kurt ^q,s   Neumann, Franz Josef ^e,s   Koltowski, Lukasz ^r,s   Mehilli, Julinda ^a,b,s   Huczek, Zenon ^r,s   Massberg, Steffen ^a,b   Parma, Zofia ^s   Lesiak, Maciej ^s   Komosa, Anna ^s   Kowara, Michal ^s   Rymuza, Bartosz ^s   Malek, Lukasz ^s   Aradi, Daniel ^s   Veress, Gábor ^s   Dézsi, András Döme ^s   Lux, Árpád ^s   Papp, Judit ^s   Kovács, Andrea ^s   Dézsi, Csaba András ^s   Amer, Sayour ^s   Ruzsa, Zoltán ^s   Róna, Szilárd ^s   Ili, Renáta ^s   Ungi, Imre ^s   Nagy, Ferenc ^s   Zweiker, Robert ^s   Tóth Gayor, Gábor ^s   Haller, Paul ^s   von Scheidt, Wolfgang ^s   Blüthgen, Andreas ^s   Leggewie, Stefan ^s   Kreider Stempfle, Hans Ulrich ^s   Remp, Thomas ^s   Kara, Kaffer ^s   Mügge, Andreas ^s   Wutzler, Alexander ^s   Fichtlscherer, Stephan ^s   Zeiher, Andreas M ^s   Seeger, Florian ^s   Hinterseer, Martin ^s   König, Andreas ^s   Lederle, Susanne ^s   Czepluch, Frauke ^s   Maier, Lars ^s   Schillinger, Wolfgang ^s   Sossalla, Samuel ^s   Hummel, Astrid ^s   Felix, Stephan ^s   Karakas, Mahir ^s   Sydow, Karsten ^s   Rudolph, Tanja ^s   Halbach, Marcel ^s   Gori, Tommaso ^s   Münzel, Thomas ^s   May, Andreas ^s   Gerstenberg, Carsten Manuel ^s   Pilecky, David ^s   Deichstetter, Markus ^s   Kääb, Stefan ^s   Löw, Anja ^s   Orban, Matthias ^s   Sattler, Stefan ^s   Deuschl, Sabine ^s   Teupser, Daniel ^s   Mudra, Harald ^s   Räder, Thomas ^s   Schütz, Torsten ^s   Vahldiek, Felix ^s   Divchev, Dimitar ^s   Ince, Hüseyin ^s   Nienaber, Christoph A ^s   Radunski, Henning ^s   Boekstegers, Peter ^s   Horstkotte, Jan ^s   Mueller, Ralf ^s   Müller, Karin ^s   Schwinger, Robert ^s   Rasp, Oliver ^s   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Military Hospital   (Hungary)

ⁱ UNIVERSITY OF PÉCS   (Hungary)

^j Department of Pediatrics   (Hungary)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^m MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁿ INSTITUTE OF CARDIOLOGY   (Poland)

^o Kliniken Nordoberpfalz AG   (Germany)

^p Heart Center Munich Bogenhausen   (Germany)

^q SIGMUND FREUD UNIVERSITY   (Austria)

^r MEDICAL UNIVERSITY OF WARSAW   (Poland)

^s Medical University of Warsaw ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG MONITORING;

ACUTE CORONARY SYNDROME; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; STROKE; TICLOPIDINE;

EID: 85028363165     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32155-4     Document Type: Article

References (38)

1. Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
2. Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
3. Antman, EM, Wiviott, SD, Murphy, SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 51 (2008), 2028–2033.
4. Becker, RC, Bassand, JP, Budaj, A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 32 (2011), 2933–2944.
5. Roffi, M, Patrono, C, Collet, JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 267–315.
6. Rollini, F, Franchi, F, Angiolillo, DJ, Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
7. Cuisset, T, Deharo, P, Quilici, J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J, 2017 published online May 16. DOI:10.1093/eurheartj/ehx175.
8. De Luca, L, D'Ascenzo, F, Musumeci, G, et al. Incidence and outcome of switching of oral platelet p2y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 13 (2017), 459–466.
9. Zettler, ME, Peterson, ED, McCoy, LA, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J 183 (2017), 62–68.
10. Motovska, Z, Hlinomaz, O, Miklik, R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 134 (2016), 1603–1612.
11. Dery, JP, Mehta, SR, Fisher, HN, et al. Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). Am Heart J 181 (2016), 26–34.
12. Gurbel, PA, Bliden, KP, Hiatt, BL, O'Connor, CM, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003), 2908–2913.
13. Tantry, US, Bonello, L, Aradi, D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
14. Aradi, D, Kirtane, A, Bonello, L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36 (2015), 1762–1771.
15. Stone, GW, Witzenbichler, B, Weisz, G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
16. Sibbing, D, Aradi, D, Jacobshagen, C, et al. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Thromb Haemost 117 (2017), 188–195.
17. Amsterdam, EA, Wenger, NK, Brindis, RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
18. Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, White, HD, Third universal definition of myocardial infarction. Eur Heart J 33 (2012), 2551–2567.
19. Mehran, R, Rao, SV, Bhatt, DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
20. Cutlip, DE, Windecker, S, Mehran, R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
21. Ndrepepa, G, Schuster, T, Hadamitzky, M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125 (2012), 1424–1431.
22. Feres, F, Costa, RA, Abizaid, A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
23. Granger, CB, Alexander, JH, McMurray, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
24. Sheikh Rezaei, S, Geroldinger, A, Heinze, G, Reichardt, B, Wolzt, M, Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014. Int J Cardiol 235 (2017), 61–66.
25. Karve, AM, Seth, M, Sharma, M, et al. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol 115 (2015), 1502–1506.
26. Bagai, A, Wang, Y, Wang, TY, et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 7 (2014), 585–593.
27. Czarny, MJ, Nathan, AS, Yeh, RW, Mauri, L, Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol 37 (2014), 505–513.
28. Cutlip, DE, Kereiakes, DJ, Mauri, L, Stoler, R, Dauerman, HL, Investigators, E, Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 8 (2015), 404–410.
29. Straub, N, Beivers, A, Lenk, E, Aradi, D, Sibbing, D, A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb Haemost 111 (2014), 290–299.
30. Price, MJ, Berger, PB, Teirstein, PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305 (2011), 1097–1105.
31. Collet, JP, Cuisset, T, Range, G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367 (2012), 2100–2109.
32. Trenk, D, Stone, GW, Gawaz, M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) Study. J Am Coll Cardiol 59 (2012), 2159–2164.
33. Cayla, G, Cuisset, T, Silvain, J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388 (2016), 2015–2022.
34. Aradi, D, Tornyos, A, Pinter, T, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63 (2014), 1061–1070.
35. Montalescot, G, Wiviott, SD, Braunwald, E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009), 723–731.
36. Ndrepepa, G, Mehilli, J, Schulz, S, et al. Patterns of presentation and outcomes of patients with acute coronary syndromes. Cardiology 113 (2009), 198–206.
37. Stone, GW, Ischaemia versus bleeding: the art of clinical decision-making. Lancet 373 (2009), 695–696.
38. Rollini, F, Franchi, F, Cho, JR, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 37 (2016), 2722–2730.